BG110103A - Супресор на ендогенния човешки гама - интерферон - Google Patents

Супресор на ендогенния човешки гама - интерферон

Info

Publication number
BG110103A
BG110103A BG11010308A BG11010308A BG110103A BG 110103 A BG110103 A BG 110103A BG 11010308 A BG11010308 A BG 11010308A BG 11010308 A BG11010308 A BG 11010308A BG 110103 A BG110103 A BG 110103A
Authority
BG
Bulgaria
Prior art keywords
gamma
inhibitor
human interferon
endogenous human
endogenous
Prior art date
Application number
BG11010308A
Other languages
English (en)
Other versions
BG66517B1 (bg
Inventor
Ivan Ivanov
Hans-Guenther Grigoleit
Genoveva Nacheva
Stefan Petrov
Original Assignee
Tigo Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tigo Gmbh filed Critical Tigo Gmbh
Priority to BG110103A priority Critical patent/BG66517B1/bg
Priority to PCT/BG2008/000025 priority patent/WO2009124362A1/en
Priority to EP08873818.2A priority patent/EP2274326B1/en
Priority to US12/735,882 priority patent/US20110135602A1/en
Publication of BG110103A publication Critical patent/BG110103A/bg
Priority to US14/243,861 priority patent/US9359421B2/en
Publication of BG66517B1 publication Critical patent/BG66517B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BG110103A 2008-04-08 2008-04-08 Супресор на ендогенния човешки гама - интерферон BG66517B1 (bg)

Priority Applications (5)

Application Number Priority Date Filing Date Title
BG110103A BG66517B1 (bg) 2008-04-08 2008-04-08 Супресор на ендогенния човешки гама - интерферон
PCT/BG2008/000025 WO2009124362A1 (en) 2008-04-08 2008-12-02 Suppressor of the endogenous interferon- gamma
EP08873818.2A EP2274326B1 (en) 2008-04-08 2008-12-02 Suppressor of the endogenous interferon- gamma
US12/735,882 US20110135602A1 (en) 2008-04-08 2008-12-02 Supperssor of the endogenous interferon-gamma
US14/243,861 US9359421B2 (en) 2008-04-08 2014-04-02 Suppressor of the endogenous interferon-gamma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BG110103A BG66517B1 (bg) 2008-04-08 2008-04-08 Супресор на ендогенния човешки гама - интерферон

Publications (2)

Publication Number Publication Date
BG110103A true BG110103A (bg) 2009-10-30
BG66517B1 BG66517B1 (bg) 2016-02-29

Family

ID=41161478

Family Applications (1)

Application Number Title Priority Date Filing Date
BG110103A BG66517B1 (bg) 2008-04-08 2008-04-08 Супресор на ендогенния човешки гама - интерферон

Country Status (4)

Country Link
US (1) US20110135602A1 (bg)
EP (1) EP2274326B1 (bg)
BG (1) BG66517B1 (bg)
WO (1) WO2009124362A1 (bg)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100016262A1 (en) * 2007-10-18 2010-01-21 Yale University Compositions and methods for reducing hepatotoxicity associated with drug administration and treating non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and associated cirrhosis
WO2009051840A2 (en) * 2007-10-18 2009-04-23 Yale University Compositions and methods for reducing hepatotoxicity associated with drug administration
WO2011041311A2 (en) * 2009-09-29 2011-04-07 Yale University Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods
BG67190B1 (bg) 2017-03-29 2020-11-16 Tigo Gmbh Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3414831A1 (de) 1984-04-19 1985-10-31 Hoechst Ag, 6230 Frankfurt Herstellung von polypeptiden mit human-gammainterferon-aktivitaet
AT393690B (de) 1987-10-08 1991-11-25 Hoffmann La Roche Homogene, rekombinante immun-interferonfragmente
US6372206B1 (en) 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
BG52073B2 (en) 1990-01-24 1996-04-30 Inst Molekuljarna Biolog Method for the preparation of recombinant human noncystein -interferon, free of n-end methionine
ZA952797B (en) 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
EP0758902A1 (en) 1994-05-10 1997-02-26 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
RU2073522C1 (ru) 1995-07-20 1997-02-20 Олег Васильевич Рубальский Лекарственный препарат противовирусного действия
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
EP1140206A4 (en) 1998-11-27 2002-04-10 Technion Res & Dev Foundation VACCINE BASED ON INTERFERON GAMMA INDUCTION FACTOR AND USE THEREOF FOR PROVIDING PROTECTION IMMUNITY AGAINST MULTIPLE SCLEROSIS
AUPP823999A0 (en) 1999-01-20 1999-02-11 University Of Queensland, The A treatment
RU2268749C2 (ru) * 1999-11-12 2006-01-27 Максиджен Холдингз Лтд КОНЪЮГАТЫ γ-ИНТЕРФЕРОНА
RU2187332C1 (ru) 2000-12-18 2002-08-20 Гапонюк Петр Яковлевич Лечебное средство
WO2002081507A2 (en) 2001-04-06 2002-10-17 Maxygen Holdings Ltd. Interferon gamma polypeptide variants
US20030082138A1 (en) * 2001-09-18 2003-05-01 Chiron Corporation Methods for treating multiple sclerosis
BG66458B1 (bg) 2005-03-21 2014-10-31 Иван Иванов Средство за конкурентно инхибиране на ендогенен гама интерферон
CA2607806A1 (en) * 2005-05-04 2006-11-16 Nautilus Biotech, S.A. Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides

Also Published As

Publication number Publication date
EP2274326B1 (en) 2014-01-01
BG66517B1 (bg) 2016-02-29
WO2009124362A1 (en) 2009-10-15
EP2274326A4 (en) 2011-09-07
US20110135602A1 (en) 2011-06-09
EP2274326A1 (en) 2011-01-19

Similar Documents

Publication Publication Date Title
EP2334185A4 (en) COMPOSITIONS AND METHODS FOR USE OF (R) -PRAMIPEXOL
ZA201000318B (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
IL199727A0 (en) Inhibitors of mek
EP2424873A4 (en) NEW GALACTOSID INHIBITORS OF GALECTINES
HK1156306A1 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases hif--4-
HK1159102A1 (en) Inhibitors of ssao activity ssao
EP2249650A4 (en) ANILINOPYRIDINE AS A FAK HEMMER
EP2231665A4 (en) NEW COMPOSITIONS AND METHODS OF USE
ZA201102604B (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
HK1161680A1 (en) Pyrazolylaminopyridines as inhibitors of fak fak
IL208483A (en) 2 limk inhibitors and preparations containing them
PL2328545T3 (pl) Zastosowanie glukozyloglicerolu
PL2133419T3 (pl) Zastosowania beta-dipeptydów cyjanoficyny
HRP20190551T1 (hr) Stabilizirani pripravci alkilirajućih agensa i metode za njihovu upotrebu
HK1160925A1 (zh) 組織蛋白酶 的用途
IL207827A0 (en) Apoaequorin-containing compositions and methods of using same
BG110103A (bg) Супресор на ендогенния човешки гама - интерферон
PL2237782T3 (pl) Zastosowanie tetrahydropirymidyn
PL2411376T3 (pl) Inhibitory nf-kb
ZA201004979B (en) Extracts of sclerocarya birrea
IL215486A0 (en) Compositions of cholinesterase inhibitors
GB0808286D0 (en) Inhibitors of HSP90
GB0803895D0 (en) Inhibitors of glyoxalase
HU0800656D0 (en) Effective use of tea-composition
GB0805693D0 (en) Combinations of P13-delta and P13-gamma kinase inhibitor compounds